Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

MDMA Member Survey Shows Repealing Medical Device Tax Would Create Jobs, Increase R&D

Washington, DC, January 29, 2015 ― A new survey conducted by the Medical Device Manufacturers Association (MDMA) shows that if the medical device tax were repealed, the overwhelming majority of medical technology innovators would increase hiring and make new investments in research and development (R&D).

Conducted over November and December in 2014, the MDMA surveye consists of over 100 responses from medical technology executives.

Top findings of the survey include:

  • 72% of companies slowed or halted job creation in the United States to pay the medical device tax.
  • 85% of respondents said that if the device tax was repealed, they would hire new employees in the U.S.
  • 80% of respondents noted that they would increase R&D investments in the cures and therapies of tomorrow
  • When asked how much they would increase their R&D budget, the average increase was 14%.

Both the House and Senate recently introduced bipartisan pieces of legislation to repeal the medical device tax in the 114th Congress.

Senators Orrin Hatch (UT) and Amy Klobuchar (MN) introduced S. 149, the “Medical Device Access and Innovation Protection Act,” along with eight of their colleagues.

On the House side, Congressmen Erik Paulsen (MN) and Ron Kind (WI) introduced H.R. 160, “The Protect Medical Innovation Act,” which currently has 272 cosponsors.

“I see firsthand every day the impact the medical device tax has on investing in new jobs and developing new technologies that improve patient care,” said Scott Huennekens, President & CEO, Volcano Corporation and Chairman of MDMA.

Huennekens continued, “This survey clearly shows what med tech innovators have long argued: if you repeal the medical device tax, it will boost job creation and increase investments in the cures and therapies of tomorrow.”

“Broad support continues to grow for repealing the medical device tax, not just in Congress, but across America’s innovation ecosystem,” said Mark Leahey, President and CEO of MDMA.  “This destructive policy has thwarted job creation and patient care for too long, and MDMA is dedicated to working with the diverse coalition of stakeholders to get repeal of the device tax across the finish line.”